Patients with MASLD exhibit a proatherogenic lipid profile characterized by high triglycerides, low-density lipoprotein cholesterol (LDL-C), reduced high-density lipoprotein (HDL-C) levels, and high apolipoprotein B (apoB) levels [72]. Here, APOB is linked to metabolic dysfunction-associated steatotic liver disease.